NOV 17, 202673 MINS READ
Croscarmellose sodium represents a specialized form of sodium carboxymethyl cellulose wherein internal cross-linking is achieved through controlled pH reduction and thermal treatment during manufacture 9. This cross-linking fundamentally alters the polymer's molecular weight distribution and functional properties compared to its non-cross-linked precursor. The fibrous nature of croscarmellose sodium exhibits a particle size distribution where 90% of particles measure ≤44.5 μm 9, though this physical dimension differs conceptually from molecular weight, which describes the polymer chain mass.
The cross-linked structure ensures that upon water absorption, individual particle integrity is maintained without forming pasty gums—a critical distinction from linear sodium carboxymethyl cellulose 9. This structural characteristic arises from covalent bonds between cellulose chains that restrict polymer chain mobility and prevent complete dissolution. The degree of cross-linking directly correlates with molecular weight distribution: higher cross-linking density typically results in a broader molecular weight range with increased proportions of high-molecular-weight fractions due to inter-chain bonding.
The molecular weight of croscarmellose sodium depends on three primary structural parameters:
These parameters collectively determine the effective molecular weight, which for croscarmellose sodium typically ranges from approximately 50,000 to 700,000 Da, though precise values depend on manufacturing conditions and intended application 6. The cross-linked nature means that traditional molecular weight measurements reflect the mass of cross-linked aggregates rather than individual linear chains.
Size exclusion chromatography (SEC), also known as gel permeation chromatography (GPC), represents the gold standard for molecular weight analysis of cellulose derivatives. A recent methodological advancement for related sodium polysaccharides demonstrates the application of universal calibration using high-performance liquid chromatography with polynomial fitting regression equations 10. This approach employs sodium polystyrene sulfonate standards with six different molecular weights to establish a cubic function regression equation 10.
The universal calibration method offers several advantages for croscarmellose sodium analysis:
For croscarmellose sodium specifically, SEC analysis requires careful consideration of the cross-linked structure. Complete dissolution is impossible due to covalent cross-links; therefore, analysis typically measures the molecular weight distribution of soluble fractions or employs specialized solvents with disaggregating agents to partially disrupt non-covalent associations while preserving the fundamental cross-linked architecture.
Advanced molecular weight characterization combines SEC with multi-angle light scattering detection, providing absolute molecular weight measurements independent of column calibration. This technique proves particularly valuable for cross-linked polymers where hydrodynamic volume may not correlate linearly with molecular weight due to structural compaction from cross-linking. The MALS approach determines weight-average molecular weight (Mw), number-average molecular weight (Mn), and polydispersity index (Mw/Mn), offering comprehensive insight into molecular weight distribution.
Intrinsic viscosity measurements in appropriate solvents (typically aqueous sodium chloride solutions to suppress polyelectrolyte effects) provide indirect molecular weight information through the Mark-Houwink equation. However, for cross-linked croscarmellose sodium, this method yields apparent molecular weights reflecting the hydrodynamic volume of swollen cross-linked particles rather than true molecular weight of individual chains. Comparative viscometry between batches can nonetheless serve as a quality control parameter correlating with functional performance.
The molecular weight of croscarmellose sodium critically affects its disintegration performance in tablet formulations. Pharmaceutical applications typically employ croscarmellose sodium at concentrations of 0.5% to 5% w/w as a tablet disintegrant 6, though recent formulation strategies demonstrate that higher concentrations (6% to 16% w/w, particularly 10% to 14% w/w) significantly enhance release rates for specific active pharmaceutical ingredients 6.
In formulations containing entacapone or nitecapone, croscarmellose sodium concentrations of at least 6% by weight, preferably 8% to 16% by weight, and especially 10% to 14% by weight, substantially increase drug release rates from oral compacted compositions 6. This concentration-dependent effect relates to the molecular weight distribution: higher molecular weight fractions provide greater swelling capacity per particle, while lower molecular weight fractions may offer faster water penetration kinetics.
For linagliptin formulations, croscarmellose sodium at 3% to 50% by weight (preferably 6% to 25%, more preferably 10% to 20%) achieves desired content uniformity without requiring milling of the active ingredient 13. This application demonstrates how appropriate molecular weight selection enables uniform drug distribution even at low active doses, addressing a critical formulation challenge.
In topical body powder formulations, croscarmellose sodium functions as a moisture absorbent at 2% to 20% w/w (preferably 5% to 20% w/w) 9. The fibrous cross-linked structure maintains particle integrity upon water absorption, preventing paste or gum formation that would occur with non-cross-linked sodium carboxymethyl cellulose 9. Molecular weight influences absorption capacity: higher molecular weight grades typically exhibit greater total absorption capacity (capable of absorbing at least 20% by weight of moisture based on total applied composition weight) 9, while lower molecular weight grades may offer faster absorption kinetics.
Compositions with more than 20% w/w croscarmellose sodium begin to exhibit the tactile sensation of the disintegrant rather than the powder diluent, and water-swollen particles become visually apparent on moist skin 9. At concentrations exceeding 40% w/w, skin feel and appearance become generally unacceptable 9. These concentration limits relate to the molecular weight-dependent swelling behavior: higher molecular weight grades swell more extensively, reaching aesthetic acceptability limits at lower concentrations.
Pharmaceutical compositions containing low-dose therapeutic agents (≤15% by weight, particularly 0.5% to 12% by weight) benefit from specific croscarmellose sodium molecular weight selection 7. In orally disintegrating tablets containing domperidone, the formulation comprises:
This formulation architecture demonstrates how croscarmellose sodium molecular weight selection (implicitly through grade selection) balances rapid disintegration with structural integrity during manufacturing and storage.
In ibandronate sodium formulations, the combination of microcrystalline cellulose with median particle size (D50) of 30 to 150 μm (preferably 100 μm) and croscarmellose sodium at 10% to 15% by weight (preferably 11% to 15%, more preferably 12% to 15%) achieves target dissolution profiles: >60% free ibandronic acid dissolved within 5 minutes and >85% within 15 minutes 11. This performance depends on molecular weight-related swelling kinetics of croscarmellose sodium interacting with the specific microcrystalline cellulose particle size distribution.
The molecular weight of croscarmellose sodium influences its interaction with other hygroscopic polymeric excipients. In compositions containing S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate, formulations include 5% to 7% by weight croscarmellose sodium alongside hydroxypropyl methylcellulose, microcrystalline cellulose, and micronized crosslinked polyvinylpyrrolidone, with total hygroscopic polymeric excipients comprising 44% to 50% by weight 123. The molecular weight distribution of croscarmellose sodium affects water partitioning among these excipients, influencing granulation behavior and final tablet properties.
In sustained release formulations, croscarmellose sodium at 1% to 30% w/w (preferably 2% to 25%, more preferably 3% to 20%) combines with alkali metal salts (sodium or potassium salts at 0.1% to 30% w/w) and alkaline agents (magnesium oxide at 0.1% to 30% w/w) to control drug dissolution while enduring gastrointestinal peristaltic movement 12. The molecular weight of croscarmellose sodium determines the balance between initial swelling (which can create a diffusion barrier) and eventual erosion (which releases drug). Higher molecular weight grades typically provide more sustained release due to greater gel strength upon hydration.
Despite the general stability of croscarmellose sodium, formulations containing active ingredients with primary amine groups may exhibit incompatibilities 13. Linagliptin, which contains a primary amine, can potentially react with excipients or their impurities in solid dosage forms 13. However, strategic formulation design incorporating croscarmellose sodium with complementary excipients overcomes these stability challenges 13.
The molecular weight of croscarmellose sodium influences stability through several mechanisms:
Conventional calcium supplement tablets containing compacted tricalcium phosphate, microcrystalline cellulose, and approximately 0.5% croscarmellose sodium demonstrate unexpected aging phenomena: acceptable initial disintegration times deteriorate to unacceptable levels after two weeks storage under stress conditions 5. This aging effect can be overcome by increasing croscarmellose sodium levels above 1% of tablet weight, though this causes excessively rapid initial disintegration 5.
The optimal solution incorporates 50% to 100% sodium lauryl sulfate (based on croscarmellose sodium weight) alongside the disintegrant, minimizing aging while maintaining acceptable disintegration characteristics 5. This aging phenomenon likely relates to molecular weight-dependent changes in the hydration shell around croscarmellose sodium particles during storage, with higher molecular weight fractions more susceptible to humidity-induced structural reorganization that reduces disintegration efficiency.
The molecular weight distribution of croscarmellose sodium influences its suitability for different manufacturing processes. In direct compression, higher molecular weight grades (typically exhibiting better flow properties due to larger effective particle size of cross-linked aggregates) facilitate uniform blending and consistent tablet weight. Lower molecular weight grades may require additional flow aids or specialized blending protocols.
For wet granulation processes, as exemplified in the preparation of S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate formulations, the procedure involves:
The molecular weight of croscarmellose sodium affects granule formation: higher molecular weight grades may create stronger inter-particle bridges during wet massing, potentially requiring adjusted liquid levels or drying conditions.
While particle size (physical dimension) differs from molecular weight (chain mass), manufacturing processes that control molecular weight often simultaneously influence particle size distribution. The specification that 90% of croscarmellose sodium particles measure ≤44.5 μm 9 reflects both the degree of cross-linking (which determines aggregate size) and post-synthesis processing (milling, classification). Formulators must recognize that different molecular weight grades may exhibit different particle size distributions, affecting blend uniformity, compaction behavior, and disintegration kinetics.
Croscarmellose sodium molecular weight selection proves critical across diverse therapeutic applications:
Antiparkinsonian agents: Entacapone and nitecapone formulations require 6% to 16% w/w croscarmellose sodium (preferably 10% to 14% w/w) to achieve adequate release rates 6. The molecular weight influences the rate of tablet disintegration in gastric fluid, directly affecting drug absorption kinetics and therapeutic onset.
Antidiabetic medications: Linagliptin tablets employ 3% to 50% w/w croscarmellose sodium (preferably 10% to 20% w/w) to ensure content uniformity without active ingredient milling 13. Molecular weight selection balances disintegration speed with manufacturing robustness, particularly important for low-dose formulations where content uniformity challenges are most acute.
Bone resorption inhibitors: Ibandronate sodium formulations utilize 10% to 15% w/w croscarmellose sodium (preferably 12% to 15% w/w) in combination with specific microcrystalline cellulose grades to achieve rapid dissolution profiles (>60% in 5 minutes, >85% in 15 minutes) 11. This rapid release minimizes esophageal contact time, reducing gastrointestinal side effects—a critical consideration for bisphosphonate therapy.
Beyond oral dosage forms, croscarmellose sodium molecular weight characteristics enable specialized applications:
Body powder formulations: At 2% to 20% w/w (preferably 5% to 20% w/w), croscarmellose sodium provides enhanced moisture absorbency (at least 20% by weight based on total applied composition) while maintaining acceptable skin feel and appearance 9. Higher molecular weight grades offer superior total absorption capacity, while lower molecular weight grades may provide faster initial absorption kinetics for immediate wetness protection.
Orally disintegrating tablets: Formulations containing 3.5% to 8% w/w croscarmellose
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| F. HOFFMANN-LA ROCHE AG | Oral solid dosage forms requiring precise content uniformity and moisture management, particularly for compounds sensitive to hygroscopic excipient interactions in direct compression and wet granulation manufacturing. | S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate Tablets | Utilizes 5-7% w/w croscarmellose sodium with optimized molecular weight distribution to achieve uniform drug distribution and controlled disintegration in formulations containing 44-50% hygroscopic polymeric excipients, ensuring stable wet granulation processing. |
| ORION CORPORATION | Antiparkinsonian oral compacted compositions requiring rapid disintegration and enhanced bioavailability for catechol derivatives with poor aqueous solubility in immediate-release tablet formulations. | Entacapone/Nitecapone Tablets (Comtan) | Employs 10-14% w/w croscarmellose sodium with specific molecular weight characteristics to substantially increase drug release rates (4x improvement), overcoming dissolution limitations of catechol-derivative active ingredients through enhanced swelling capacity. |
| LABORATORIOS LICONSA S.A. | Bisphosphonate bone resorption inhibitor formulations requiring ultra-rapid dissolution profiles to reduce gastrointestinal side effects in direct compression tablet manufacturing for osteoporosis treatment. | Ibandronate Sodium Tablets | Incorporates 12-15% w/w croscarmellose sodium with controlled molecular weight distribution combined with 100 μm D50 microcrystalline cellulose, achieving >60% dissolution within 5 minutes and >85% within 15 minutes, minimizing esophageal contact time. |
| SANOVEL ILAC SANAYI VE TICARET A.S. | Low-dose antidiabetic DPP-4 inhibitor solid dosage forms (2-80% API) requiring exceptional content uniformity and chemical stability despite potential amine-excipient incompatibilities in oral tablet formulations. | Linagliptin Tablets | Uses 10-20% w/w croscarmellose sodium with optimized molecular weight to achieve desired content uniformity without requiring active ingredient milling, overcoming stability challenges associated with primary amine groups through strategic excipient selection. |
| COMBE INCORPORATED | Topical moisture-absorbent powder formulations for skin protection requiring high water absorption capacity, rapid moisture uptake kinetics, and cosmetically acceptable tactile properties for wetness and irritation prevention. | Topical Body Powder | Contains 5-20% w/w croscarmellose sodium with fibrous cross-linked structure (90% particles ≤44.5 μm) providing at least 20% moisture absorption capacity by weight while maintaining particle integrity without forming pasty gums, ensuring acceptable skin feel and appearance. |